This peptide inhibitor, or other inhibitors of E6AP, can be used to test the possibility of relieving PML from proteasomal destruction in cancers where E6AP is elevated such as prostate adenocarcinoma and B-lymphoma (Srinivasan and Nawaz, 2011; Wolyniec et al., 2012b). This evidence concerns the gene PML and prostate adenocarcinoma.